PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Consistently, in another randomized controlled trial (NCT00885313), it was tested whether the PNPLA3 I148M variant is associated with the response to DHA (250 or 500 mg/day) in 60 children with NAFLD for 24 months.